Compare Agora Inc (API) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agora Inc vs Novartis AG — how do they compare? Agora Inc trades at $4.68 (market cap $385.97M), while Novartis AG trades at $155.08 (market cap $298.18B). The key difference: Novartis AG is far larger — about 772.5× Agora Inc's market cap, and Novartis AG pays a 3.02% dividend while Agora Inc pays none. Which is the better fit depends on your goals.
| API | NVS | |
|---|---|---|
Market Cap | $385.97M | $298.18B |
Sector | Technology | Health |
52-Week High | $5.26 | $168.62 |
52-Week Low | $3.24 | $118.55 |
Enterprise Value | $138.95M | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agora, Inc. (API) trades at $4.46, up 7.47% today, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.01, beating expectations, and shows improving fundamentals with 2025 revenue of $141.06M and net income of $9.53M. Recent news highlights its Q2 2026 earnings report scheduled for August 13, 2026.
Outlook is positive with analyst consensus at 60% buy, supported by a low P/B of 0.68 and strong cash flow growth. Risks include high P/E of 50.68 and competitive pressures in AI technology. The stock offers value potential if earnings growth continues, but volatility may persist near-term.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agora Inc
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Read more on API →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
